MCL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Mcl-1 has also been implicated as a key element in the resistance to conventional cancer therapies in certain human malignancies, including chronic myeloid leukemia, HCC, and cholangiocarcinoma[43-46].